Increased expression of erythropoiesis inhibiting cytokines (IFN-γ, TNF-α, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy

Journal of the American Society of Nephrology

Volumn 14, Issue 7, 2003, Pages 1776-1784

  Cooper, Angela C ^a,b   Mikhail, Ashraf ^a   Lethbridge, Mark W ^a   Kemeny, D Michael ^a   MacDougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; ENALAPRIL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; IRBESARTAN; IRON; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ERYTHROPOIESIS; FLOW CYTOMETRY; HEMODIALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0037530608     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000071514.36428.61     Document Type: Article

References (39)

1. Shanks JH, Hill CM, Lappin TR, Maxwell AP: Localization of erythropoietin gene expression in proximal renal tubular cells detected by digoxigenin-labelled oligonucleotide probes. J Pathol 179: 283-287, 1996
2. Barany P: Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 16: 224-227, 2001
3. Drueke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16[Suppl 7]: 25-28, 2001
4. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32: S133-S141, 1998
5. Macdougall IC: Present and future strategies in the treatment of renal anaemia. Nephrol Dial Transplant 16[Suppl 5]: 50-55, 2001
6. Stenvinkel P: The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16[Suppl 7]: 36-40, 2001
7. Macdougall IC, Cooper A: The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 17[Suppl 1]: 48-52, 2002
8. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-gamma and TNF-alpha. J Investig Med 47: 204-211, 1999
9. Means RT Jr, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647, 1992
10. Dai CH, Price JO, Brunner T, Krantz SB: Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 91: 1235-1242, 1998
11. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37: S182-238, 2001
12. Jung T, Schauer U, Heusser C, Neumann C, Rieger C: Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159: 197-207, 1993
13. Prussin C, Metcalfe DD: Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 188: 117-128, 1995
14. Cooper AC, Breen CP, Vyas B, Ochola J DMK, IC M: Poor response to recombinant erythropoietin is associated with loss of T lymphocyte CD28 expression and altered interleukin-10 production. Nephrol Dial Transplant 18: 133-140, 2002
15. Girndt M, Sester U, Kaul H, Kohler H: Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 9: 1689-1696, 1998
16. Selleri C, Maciejewski JP, Sato T, Young NS: Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87: 4149-4157, 1996
17. Means RT Jr, Krantz SB: Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 91: 416-419, 1993
18. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765, 2001
19. Oehler L, Kollars M, Bohle B, Berer A, Reiter E, Lechner K, Geissler K: Interleukin-10 inhibits burst-forming unit-erythroid growth by suppression of endogenous granulocyte-macrophage colony-stimulating factor production from T cells. Exp Hematol 27: 217-223, 1999
20. Xi X, Schlegel N, Caen JP, Minty A, Fournier S, Caput D, Ferrara P, Han ZC: Differential effects of recombinant human interleukin-13 on the in vitro growth of human haemopoietic progenitor cells. Br J Haematol 90: 921-927, 1995
21. Sakamoto O, Hashiyama M, Minty A, Ando M, Suda T: Interleukin-13 selectively suppresses the growth of human macrophage progenitors at the late stage. Blood 85: 3487-3493, 1995
22. Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12: 1549-1557, 2001
23. Honkanen E, Gronhagen-Riska C, Teppo AM, Maury CP, Meri S: Acute-phase proteins during hemodialysis: Correlations with serum interleukin-1 beta levels and different dialysis membranes. Nephron 57: 283-287, 1991
24. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 47: 559-565, 1995
25. Memoli B, Marzano L, Bisesti V, Andreucci M, Guida B: Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 10: 2171-2176, 1999
26. Pomianek MJ, Colton CK, Dinarello CA, Miller LC: Synthesis of tumor necrosis factor alpha and interleukin-1 receptor antagonist, but not interleukin-1, by human mononuclear cells is enhanced by exposure of whole blood to shear stress. ASAIO J 42: 52-59, 1996
27. Girndt M, Sester U, Sester M, Kaul H, Kohler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14: 2807-2810, 1999
28. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986
29. Street NE, Mosmann TR: Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5: 171-177, 1991
30. Sester U, Sester M, Hauk M, Kaul H, Kohler H, Gimdt M: T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 15: 1217-1223, 2000
31. Daichou Y, Kurashige S, Hashimoto S, Suzuki S: Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 83: 237-245, 1999
32. Libetta C, Rampino T, Dal Canton A: Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 38: 286-295, 2001
33. Noble A, Macary PA, Kemeny DM: IFN-gamma and IL-4 regulate the growth and differentiation of CD8+ T cells into sub-populations with distinct cytokine profiles. J Immunol 155: 2928-2937, 1995
34. MacAry PA, Holmes BJ, Kemeny DM: Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE. J Immunol 160: 580-587, 1998
35. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR: Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254: 279-282, 1991
36. Maggi E, Giudizi MG, Biagiotti R, Annunziato F, Manetti R, Piccinni MP, Parronchi P, Sampognaro S, Giannarini L, Zuccati G, et al: Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 180: 489-495, 1994
37. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
38. Stenvinkel P, Chung SH, Heimburger O, Lindholm B: Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 21[Suppl 3]: S157-S162, 2001
39. Koury MJ, Bondurant MC: Erythropoietin retards DNA break-down and prevents programmed death in erythroid progenitor cells. Science 248: 378-381, 1990